Quest Diagnostics Inc vs Logitech International SA — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Logitech International SA trades at $101.34 (market cap $14.46B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Logitech International SA pays the higher dividend (1.63%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Logitech International SA for 92 Days on average.
| DGX | LOGI | |
|---|---|---|
Market Cap | $25.48B | $14.46B |
Volume | 941,866 | 349,547 |
Sector | Health | Technology |
52-Week High | $247.45 | $126.69 |
52-Week Low | $173.49 | $85.84 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | $31.23B | $12.79B |
Dividend Yield | 1.49% | 1.63% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
Logitech (LOGI) trades at $102.18, down slightly (-0.22%) on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 16.28% net income margin and 35.29% ROE, supported by recent earnings beats. Recent news highlights product launches like the Zone Vibe Pro headset and a partnership with SEGA for Crazy Taxi: World Tour, indicating active business development.
The outlook is cautiously optimistic, with a consensus price target of $107 offering potential upside. Key opportunities include sustained earnings growth and new product cycles, while risks involve competitive pressures in the peripheral market and potential supply chain disruptions, as noted by the CEO addressing chip shortages (WSJ, 2026-09-30).
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →